Targeting CDK11 in Rhabdoid Tumor of the Kidney
Open Access
Abstract
Background: Rhabdoid tumor of the kidney (RTK) is a highly aggressive pediatric malignancy characterized by biallelic SMARCB1 loss, resulting in aberrant MYC pathway activation and cell cycle regulation. MYC-activated tumors are vulnerable in splicing functions and sensitive to splicing inhibitors. Therefore, in this study, cyclin-dependent kinase 11 (CDK11), which regulates both cell cycle and RNA splicing, was tested as a therapeutic target in RTK. Methods: CDK11A/B expression was analyzed using the TARGET-RT database. The therapeutic efficacy of the CDK11 inhibitor OTS964 was evaluated in two RTK cell lines (G401 and JMU-RTK-2) and a JMU-RTK-2 xenograft mouse model. Cytotoxicity, apoptosis, cell cycle, and RNA splicing were examined using the Sulforhodamine B assay, immunoblotting, flow cytometry, and RT-PCR. Results: CDK11B, but not CDK11A, was significantly upregulated in RTK and correlated with the poor survival. OTS964 inhibited RTK cell growth in vitro with the IC50 of 33.1 nM (G401) and 19.3 nM (JMU-RTK-2) and significantly prolonged survival in vivo (median survival: 46.5 vs. 37.0 days, p < 0.01) without marked toxicity. Mechanistically, OTS964 induced G2/M cell cycle arrest and p53 upregulation, disrupted RNA splicing via SF3B1 dephosphorylation, and ultimately led to apoptosis through caspase-3 activation. Conclusions: CDK11 inhibition by OTS964 effectively suppresses RTK growth through cell cycle arrest and RNA splicing inhibition, leading to apoptosis. OTS964 shows potent anti-tumor activity and tolerability, supporting CDK11 as a promising therapeutic target for RTK and related SMARCB1-deficient cancers.Keywords
Funding Information
- Cancer Research Coordinating Committee
- Keaton's Child Cancer Alliance
- St. Baldrick’s Foundation Summer Fellowship
- Japan Society for the Promotion of Science (JSPS) Overseas Challenge Program for Young Researchers (202280180)
- Uehara Memorial Foundation (202130021)
- Ito Foundation for the Promotion of Medical Sciences (2022-22)
This publication has 37 references indexed in Scilit:
- CDK 11 inhibition induces cytoplasmic p21
WAF
1
splice variant by p53 stabilisation and SF 3 B 1 inactivationMolecular Oncology, 2025
- Therapeutic potential of CDK11 in cancerClinical and Translational Medicine, 2023
- Crystal structure of the CDK11 kinase domain bound to the small-molecule inhibitor OTS964Structure, 2022
- Improving Cancer Detection and Treatment by pH‐Sensitive Peptide Nanoparticle Drug Delivery Platform: Pharmacokinetics, Toxicity, and Immunogenicity ProfileAdvanced NanoBiomed Research, 2021
- Roles of CDK/Cyclin complexes in transcription and pre-mRNA splicing: Cyclins L and CDK11 at the cross-roads of cell cycle and regulation of gene expressionSeminars in Cell & Developmental Biology, 2020
- Liposomal OTS964, a TOPK inhibitor: a simple method to estimate OTS964 association with liposomes that relies on enhanced OTS964 fluorescence when bound to albuminDrug Delivery and Translational Research, 2019
- p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid TumorsCancer Cell, 2019
- [18F]FE-OTS964: a Small Molecule Targeting TOPK for In Vivo PET Imaging in a Glioblastoma Xenograft ModelMolecular Imaging and Biology, 2018
- Mechanisms by which SMARCB1 loss drives rhabdoid tumor growthCancer Genetics, 2014
- Epidemiology of rhabdoid tumors of early childhoodPediatric Blood & Cancer, 2012